AIM： To investigate the genetic characteristics and pathogenicity of hepatitis E virus （HEV） and assess the potential risk factors for sporadic hepatitis E.
Objective To investigate the association between HBV genotypes and characteristics of rt A181 mutation. Methods Total of 85 chronic hepatitis B(CHB) patients who appeared rt A181 mutation after nucleos(t)ide analogs(N...Objective To investigate the association between HBV genotypes and characteristics of rt A181 mutation. Methods Total of 85 chronic hepatitis B(CHB) patients who appeared rt A181 mutation after nucleos(t)ide analogs(NAs) therapy were enrolled in this study. Levels of serum ALT, AST, HBV DNA and HBs Ag titers were monitored during therapy. HBV reverse transcriptase genes were amplified and sequenced to identify genotypes and resistance mutations. Virions and HBs Ag in Hep G2 cell with rt A181 mutation were also compared between genotypes B and C. Results The majority of sera contained HBV genotypes B(15.7%) and C(84.3%). There were no significant difference of rt A181 mutant patterns between genotypes(P > 0.05). After emergence of rt A181 mutation, serum ALT, AST, HBV DNA levels and HBs Ag titers were decreased than that at baseline(P < 0.05), while these characteristics were not different between genotypes B and C(P > 0.05). In cellular experiment, there were no significant differences between genotypes B and C not only in HBV virions but also in HBs Ag titres(P > 0.05). Conclusions No differences of clinical characteristics and cellular results were found in rt A181 mutation of HBV genotypes B and C.展开更多
基金Supported by The 863 National High Technology Research and Development Program of China,No.2006A02Z453the National Natural Science Foundation of China,No.30570063
文摘AIM： To investigate the genetic characteristics and pathogenicity of hepatitis E virus （HEV） and assess the potential risk factors for sporadic hepatitis E.
文摘Objective To investigate the association between HBV genotypes and characteristics of rt A181 mutation. Methods Total of 85 chronic hepatitis B(CHB) patients who appeared rt A181 mutation after nucleos(t)ide analogs(NAs) therapy were enrolled in this study. Levels of serum ALT, AST, HBV DNA and HBs Ag titers were monitored during therapy. HBV reverse transcriptase genes were amplified and sequenced to identify genotypes and resistance mutations. Virions and HBs Ag in Hep G2 cell with rt A181 mutation were also compared between genotypes B and C. Results The majority of sera contained HBV genotypes B(15.7%) and C(84.3%). There were no significant difference of rt A181 mutant patterns between genotypes(P > 0.05). After emergence of rt A181 mutation, serum ALT, AST, HBV DNA levels and HBs Ag titers were decreased than that at baseline(P < 0.05), while these characteristics were not different between genotypes B and C(P > 0.05). In cellular experiment, there were no significant differences between genotypes B and C not only in HBV virions but also in HBs Ag titres(P > 0.05). Conclusions No differences of clinical characteristics and cellular results were found in rt A181 mutation of HBV genotypes B and C.
